Cent Eur J Public Health 2016, 24(3):223-230

Association of EGF, IGFBP-3 and TP53 Gene Polymorphisms with Major Depressive Disorder in Slovak Population

Silvia Mahmood1,2, Andrea Evinová2, Mária ©kereňová3, Igor Ondrejka4, Ján Lehotský2,5
1 Department of Molecular Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Biomedical Centre Martin (BioMed Martin), Martin, Slovakia
2 Department of Medical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia
3 Department of Clinical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin University Hospital, Martin, Slovakia
4 Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Clinic of Psychiatry, Martin University Hospital, Martin, Slovakia
5 Department of Neurosciences, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Biomedical Centre Martin (BioMed Martin), Martin, Slovakia

Background: Major depressive disorder (MDD) is a main public health concern worldwide. Despite extensive investigations, the exact mechanisms responsible for MDD have not been identified. Epidermal growth factor (EGF) and insulin growth factor binding protein-3 (IGFBP-3) are involved in brain function. Tumour suppressor protein p53 is widely involved in neuronal death in response to different forms of acute insults and neurological disorders. The present study focuses on the possible associations of the single-nucleotide polymorphisms (SNP) of EGF A61G (rs4444903), IGFBP-3 C32G (rs2854746) and TP53 G72C (rs1042522) genes with MDD risk in the Slovak population.

Methods: The present case-control association study was carried out in 111 confirmed MDD patients and 207 healthy subjects. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism methods.

Results: Logistic regression analysis showed no association between SNPs of selected genes and MDD risk in the Slovak population. However, the stratification of individuals by gender revealed that males carrying IGFBP-3 G alleles (G32G or GG) had marginally increased risk for developing MDD as compared to CC homozygous males (p=0.09). In women, inverse association was observed between SNP rs1042522 and MDD risk (p=0.04 for recessive model).

Conclusion: Our results suggest the protective effect of minor allele 72C of TP53 gene towards MDD. The disruption of mechanisms involved in cell survival and death regulation may be involved in pathophysiology of MDD.

Keywords: major depressive disorder, EGF, IGFBP-3, p53, SNP, Slovak population

Received: February 2, 2015; Revised: April 27, 2016; Accepted: April 27, 2016; Published: September 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mahmood S, Evinová A, ©kereňová M, Ondrejka I, Lehotský J. Association of EGF, IGFBP-3 and TP53 Gene Polymorphisms with Major Depressive Disorder in Slovak Population. Cent Eur J Public Health. 2016;24(3):223-230. PubMed PMID: 27755861.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol. 2005 Aug;15(4):357-76. Go to original source... Go to PubMed...
    2. Van de Velde S, Bracke P, Levecque K. Gender differences in depression in 23 European countries. Cross-national variation in the gender gap in depression. Soc Sci Med. 2010 Jul;71(2):305-13. Go to original source... Go to PubMed...
    3. Celano CM, Freudenreich O, Fernandez-Robles C, Stern TA, Caro MA, Huffman JC. Depressogenic effects of medications: a review. Dialogues Clin Neurosci. 2011;13(1):109-25. Go to original source...
    4. Lohoff FW. Overview of the genetics of Major Depressive Disorders. Curr Psychiatry Rep. 2010 Dec;12(6):539-46. Go to original source... Go to PubMed...
    5. Insel, TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry. 2006 Jan;11(1):11 Go to original source... Go to PubMed...
    6. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008 Oct 16;455(7215):894-902. Go to original source... Go to PubMed...
    7. Fournier NM, Duman RS. Role of VEGF in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res. 2012 Feb 14;227(2):440-9. Go to original source... Go to PubMed...
    8. Duman RS, Li N. A neurotrophic hypothesis of depression: role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci. 2012 Sep 5;367(1601):2475-84. Go to original source... Go to PubMed...
    9. Evinova A, Babusikova E, Straka S, Ondrejka I, Lehotsky J. Analysis of genetic polymorphisms of brain-derived neurotrophic factor and methylenetetrahydrofolate reductase in depressed patients in a Slovak (Caucasian) population. Gen Physiol Biophys. 2012 Dec;31(4):415-22. Go to original source... Go to PubMed...
    10. Qian J, Zhou H, Chen J, Ding Q, Cao Q, Qin C, et al. Genetic polymorphisms in IGF-I and IGFBP-3 are associated with prostate cancer in the Chinese population. PLoS One. 2014 Feb 21;9(2):e85609. doi: 10.1371/journal.pone.0085609. Go to original source... Go to PubMed...
    11. Kopczak A, Stalla GK, Uhr M, Lucae S, Hennings J, Ising M, et al. IGF-I in major depression and antidepressant treatment response. Eur Neuropsychopharmacol. 2015 Jun;25(6):864-72. Go to original source... Go to PubMed...
    12. Tu KY, Wu MK, ChenYW, Lin PY, Wang HY, Wu CK, et al. Significantly higher peripheral insulin-like growth factor-1 levels in patients with major depressive disorder or bipolar disorder than in healthy controls: a metaanalysis and review under guideline of PRISMA. Medicine (Baltimore). 2016 Jan;95(4):e2411. doi: 10.1097/MD.0000000000002411. Go to original source... Go to PubMed...
    13. Bot M, MilaneschiY, Penninx BW, Drent ML. Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users. Psychoneuroendocrinology. 2016 Jun;68:148-55. Go to original source... Go to PubMed...
    14. Kim YK, Na KS, Hwang JA, Yoon HK, Lee HJ, Hahn SW, et al. High insulin-like growth factor-1 in patients with bipolar I disorder: a trait marker? J Affect Disord. 2013 Nov;151(2):738-43. Go to original source... Go to PubMed...
    15. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009 Aug;30(5):417-37. Go to original source... Go to PubMed...
    16. Kalluri HS, Dempsey RJ. IGFBP-3 inhibits the proliferation of neural progenitor cells. Neurochem Res. 2011 Mar;36(3):406-11. Go to original source... Go to PubMed...
    17. Basta-Kaim A, Szczesny E, Glombik K, Slusarczyk J, Trojan E, Tomaszewski KA, et al. Prenatal stress leads to changes in IGF-1 binding proteins network in the hippocampus and frontal cortex of adult male rat. Neuroscience. 2014 Aug 22;274:59-68. Go to original source... Go to PubMed...
    18. Vogel T. Insulin/IGF-signalling in embryonic and adult neural proliferation and differentiation in the mammalian central nervous system. In: Wislet-Gendebien S, editor. Trends in cell signaling pathways in neuronal fate decision [Internet]. Rijeka: InTech; 2013. p. 37-73 [cited 2016 Apr 27]. Available from: http://www.intechopen.com/books/trends-in-cellsignaling-pathways-in-neuronal-fate-decision/insulin-igf-signalling-inembryonic-and-adult-neural-proliferation-and-differentiation-in-themammal. Go to original source...
    19. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, et al. Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab. 2001 Mar;86(3):1274-80. Go to original source...
    20. Jernström H, Deal C, Wilkin F, Chu W, Tao Y, Majeed N, et al. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):377-84.
    21. Zou T, Fleisher AS, Kong D, Yin J, Souza RF, Wang S, et al. Sequence alterations of insulin-like growth factor binding protein 3 in neoplastic and normal gastrointestinal tissues. Cancer Res. 1998 Nov 1;58(21):4802-4.
    22. Morimoto LM, Newcomb PA, White E, Bigler J, Potter JD. Insulin-like growth factor polymorphisms and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1204-11. Go to original source... Go to PubMed...
    23. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem. 1979;48:193-216. Go to original source... Go to PubMed...
    24. Mahmood S, Kme»ová Sivoňová M, Matáková T, Dobrota D, Dzian A, Wsolova L, et al. Association of EGF and p53 gene polymorphisms and colorectal cancer risk in the Slovak population. Cent Eur J Med. 2014;9(3):405-16. Go to original source...
    25. Iwakura Y, Zheng Y, Sibilia M, Abe Y, Piao YS, Yokomaku D, et al. Qualitative and quantitative re-evaluation of epidermal growth factorErbB1 action on developing midbrain dopaminergic neurons in vivo and in vitro: target-derived neurotrophic signaling (Part 1). J Neurochem. 2011 Jul;118(1):45-56. Go to original source... Go to PubMed...
    26. Eda T, Mizuno M, Araki K, Iwakura Y, Namba H, Sotoyama H, et al. Neurobehavioral deficits of epidermal growth factor-overexpressing transgenic mice: impact on dopamine metabolism. Neurosci Lett. 2013 Jun 28;547:21-5. Go to original source... Go to PubMed...
    27. Tian W, Zhang J, Zhang K, Yang H, Sun Y, Shen Y, et al. A study of the functional significance of epidermal growth factor in major depressive disorder. Psychiatr Genet. 2012 Aug;22(4):161-7. Go to original source... Go to PubMed...
    28. Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K, et al. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry. 2002;7(7):673-82. Go to original source... Go to PubMed...
    29. Hänninen K, Katila H, Anttila S, Rontu R, Maaskola J, Hurme M, et al. Epidermal growth factor a61g polymorphism is associated with the age of onset of schizophrenia in male patients. J Psychiatr Res. 2007 JanFeb;41(1-2):8-14. Go to original source... Go to PubMed...
    30. Lee KY, Ahn YM, Joo EJ, Joo YH, Chang JS, Yoo HY, et al. Partial evidence of an association between epidermal growth factor A61G polymorphism and age at onset in male schizophrenia. Neurosci Res. 2006 Dec;56(4):356-62. Go to original source... Go to PubMed...
    31. Shahbazi M, Pravica V, Nasreen N, Fakhoury H, Fryer AA, Strange RC, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet. 2002 Feb 2;359(9304):397-401. Go to original source... Go to PubMed...
    32. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997 Feb 7;88(3):323-31. Go to original source... Go to PubMed...
    33. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, Zelnick CR, et al. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 1997 Mar 17;16(6):1391-400. Go to original source... Go to PubMed...
    34. Zhang C, Wu Z, Hong W, Wang Z, Peng D, Chen J, et al. Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. J Affect Disord. 2014 Feb;155:288-94. Go to original source... Go to PubMed...
    35. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARCTP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 2002 Jun;19(6):607-14. Go to original source... Go to PubMed...
    36. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 1999 Feb;19(2):1092-100. Go to original source...
    37. Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene. 1997 Aug 18;15(8):887-98. Go to original source... Go to PubMed...
    38. Azzam GA, Frank AK, Hollstein M, Murphy ME. Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle. 2011;10(9):1352-5. Go to original source... Go to PubMed...
    39. SNP& Variation Suite™. Version 8.x [software]. Bozeman, MT: Golden Helix, Inc. Available from http://www.goldenhelix.com
    40. Szczęsny E, Slusarczyk J, Głombik K, Budziszewska B, Kubera M, Lasoń W, et al. Possible contribution of IGF-1 to depressive disorder. Pharmacolog. Pharmacol Rep. 2013;65(6):1622-31. Go to original source... Go to PubMed...
    41. Harrela M, Koistinen H, Kaprio J, Lehtovirta M, Tuomilehto J, Eriksson J, et al. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest. 1996 Dec 1;98(11):2612-5. Go to original source... Go to PubMed...
    42. Licht CM, van Turenhout LC, Deijen JB, Koppes LL, van Mechelen W, Twisk JW, et al. The association between igf-1 polymorphisms, igf-1 serum levels, and cognitive functions in healthy adults: the Amsterdam Growth and Health Longitudinal Study. Int J Endocrinol. 2014;2014:181327. doi: 10.1155/2014/181327. Go to original source... Go to PubMed...
    43. D'Aloisio AA. Evaluation of insulin-like growth factor polymorphisms with prevalence and size of uterine leiomyomata [dissertation]. Chapel Hill: University of North Carolina; 2007.
    44. Duron E, Funalot B, Brunel N, Coste J, Quinquis L, Viollet C, et al. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Alzheimer's disease. J Clin Endocrinol Metab. 2012 Dec;97(12):4673-81. Go to original source... Go to PubMed...
    45. Green CJ, Holly JM, BayerA, Fish M, Ebrahim S, Gallacher J, et al. The role of IGF-I, IGF-II, and IGFBP-3 in male cognitive aging and dementia risk: the Caerphilly Prospective Study. JAlzheimers Dis. 2014;41(3):86775. Go to original source...
    46. Johansson P, Åberg D, Johansson JO, Mattsson N, Hansson O, Ahrén B, et al. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology. 2013 Sep;38(9):172937. Go to original source... Go to PubMed...
    47. Emeny RT, Bidlingmaier M, Lacruz ME, Linkohr B, PetersA, Reincke M, et al. Mind over hormones: sex differences in associations of well-being with IGF-I, IGFBP-3 and physical activity in the KORA-Age study. Exp Gerontol. 2014 Nov;59:58-64. Go to original source... Go to PubMed...
    48. Cheng I, DeLellis Henderson K, Haiman CA, Kolonel LN, Henderson BE, Freedman ML, et al. Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab. 2007 Sep;92(9):36606. Go to original source... Go to PubMed...
    49. D'Aloisio AA, Schroeder JC, North KE, Poole C, West SL, Travlos GS, et al. IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among African American and Caucasian women. Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):954-66. Go to original source... Go to PubMed...
    50. Mill J, Petronis A. Molecular studies of major depressive disorder: the epigenetic perspective. Mol Psychiatry. 2007 Sep;12(9):799-814. Go to original source... Go to PubMed...
    51. Lim YJ, Kim JW, Song JY, Hong MS, Jin SY, Yoon SH, et al. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett. 2005 Feb 21;374(3):157-60. Go to original source... Go to PubMed...
    52. Watanabe Y, Fukui N, Muratake T, Kaneko N, Someya T. No association of EGF polymorphism with schizophrenia in a Japanese population. Neuroreport. 2005 Mar 15;16(4):403-5. Go to original source... Go to PubMed...
    53. Anttila S, Illi A, Kampman O, Mattila KM, Lehtimäki T, Leinonen E. Association of EGF polymorphism with schizophrenia in Finnish men. Neuroreport. 2004 May 19;15(7):1215-8. Go to original source... Go to PubMed...
    54. Eilat E, Mendlovic S, Doron A, Zakuth V, Spirer Z. Increased apoptosis in patients with major depression: a preliminary study. J Immunol. 1999 Jul 1;163(1):533-4.
    55. Tenti P,Vesentini N, Rondo Spaudo M, Zappatore R, Migliora P, Carnevali L, et al. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy. Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):435-8.
    56. Scheckenbach K, Lieven O, Götte K, Bockmühl U, Zotz R, Bier H, et al. p53 codon 72 polymorphic variants, loss of allele-specific transcription, and human papilloma virus 16 and/or 18 E6 messenger RNA expression in squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1805-9. Go to original source...
    57. Gomez-Sanchez JC, Delgado-Esteban M, Rodriguez-Hernandez I, Sobrino T, Perez de la Ossa N, Reverte S, et al. The human Tp53 Arg72Pro polymorphism explains different functional prognosis in stroke. J Exp Med. 2011 Mar 14;208(3):429-37. Go to original source... Go to PubMed...
    58. Karlović D, Buljan D. Apoptosis - the potential pathophysiological mechanism in mood disorders modifiable by lithium salts. Biochemia Medica. 2008;18(3):291-310. (In English, Croatian.) Go to original source...

    Return to the content